Genotype-phenotype correlations for cataracts in neurofibromatosis 2

Journal of Medical Genetics

Volumn 40, Issue 10, 2003, Pages 758-760

  Baser, M E ^d   Kuramoto, L ^a   Joe, H ^a   Friedman, J M ^a   Wallace, A J ^b   Ramsden, R T ^c   Evans, D G R ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ST MARY S HOSPITAL   (United Kingdom)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ANALYTIC METHOD; ANAMNESIS; ARTICLE; CATARACT; CELL DIFFERENTIATION; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENE DELETION; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HUMAN; LENS EPITHELIUM; LENS FIBER; MAJOR CLINICAL STUDY; MALE; MOSAICISM; NEUROFIBROMATOSIS; ONSET AGE; PHENOTYPE; PRIORITY JOURNAL; REGISTER; SCREENING; SINGLE STRAND CONFORMATION POLYMORPHISM; SLIT LAMP; STATISTICAL ANALYSIS;

EID: 0142147123     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.40.10.758     Document Type: Article

References (16)

1. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, Eldridge R, Kley N, Menon AG, Pulaski K, Haase VH, Ambrose CM, Munroe D, Bove C, Haines JL, Martuza RL, MacDanald ME, Seizinger BR, Short MP, Buckler AJ, Gusella JF. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor (published erratum appears in Cell 1993;75:826). Cell 1993;72:791-800.
2. Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, Hoang-Xuan K, Demczuk S, Desmaze C, Plougastel B, Pulst SM, Lenoir G, Bijlsma E, Fashold R, Dumanski J, de Jong P, Parry D, Eldridge R, Aurias A, Delattre O, Thomas G. Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 1993;363:515-21.
3. Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 1994;52:450-61.
4. Mautner VF, Lindenau M, Baser ME, Hazim W, Tatagiba M, Haase W, Samii M, Wais R, Pulst SM. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery 1996;38:880-5.
5. Ragge NK, Baser ME, Klein J, Nechiporuk A, Sainz J, Pulst SM, Riccardi VM. Ocular abnormalities In neurofibromatosis 2. Am J Ophthalmol 1995;120:634-41.
6. Claudio JO, Veneziale RW, Menko AS, Rouleau GA. Expression of schwannomin in lens and Schwann cells. Neuroreport 1997;8:2025-30.
7. Evans DGR, Trueman L, Wallace A, Collins S, Strachan T. Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. J Med Genet 1998;35:450-5.
8. Ashford J, Sowden R. Multivariate probit analysis. Biometrics 1970;26:535-46.
9. Evans DGR, Huson SM, Donnai D, Neary W, Blair V, Newton V, Harris R. A clinical study of type 2 neurofibromatosis. Q J Med 1992;84:603-18.
10. Klein BE, Klein R, Linton KL. Prevalence of age-related lens opacities in a population. The Beaver Dam Eye Study. Ophthalmology 1992;99:546-52.
11. Kluwe L, Mautner VF, Heinrich B, Dezube R, Jacoby LB, Friedrich RE, MacCollin M. Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. J Med Genet 2003;40:109-14.
12. Moyhuddin A, Baser ME, Watson C, Purcell S, Ramsden RT, Heiberg A, Wallace A, Evans DGR. Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring. J Med Genet 2003;40:459-63.
13. Bruder CEG, Hirvelä C, Tapia-Paez I, Fransson I, Segraves R, Hamilton G, Zhang XX, Evans DG, Wallace AJ, Baser ME, Zucman-Rossi J, Hergersberg M, Boltshauser E, Papi L, Rouleau GA, Poptodorov G, Jordanova A, Rask-Andersen H, Kluwe L, Mautner V, Sainio M, Hung G, Mathiesen T, Möller C, Pulst SM, Harder H, Heiberg A, Honda M, Niimura M, Sahlén S, Blennow E, Alberton DG, Pinkel D, Dumanski JP. High-resolution deletion analysis of constitutional DNA from neurofibromatosis type 2 (NF2) patients using microarray-CGH. Hum Mol Genet 2001;10:271-82.
14. Zucman-Rossi J, Legoix P, Sarkissian HD, Cheret G, Sor F, Bernardi A, Cazes L, Giraud S, Ollagnon E, Lenoir G, Thomas G. NF2 gene in neurofibromatosis type 2 patients. Hum Mol Genet 1998;7:2095-101.
15. Zhao Y, Kuman RA, Baser ME, Evans DGR, Wallace A, Kluwe L, Mautner VF, Parry DM, Rouleau GA, Joe H, Friedman JM. Intrafamilial correlation of clinical manifestations of in neurofibromatosis 2 (NF2). Genet Epidemiol 2002;23:245-59.
16. MacCollin M, Mautner VF. The diagnosis and management of neurofibromatosis 2 in childhood. Semin Pediatr Neurol 1998;5:243-52.